Who Makes Ozempic: The Complete Manufacturing and Supply Chain Story Behind the World's Most Prescribed GLP-1

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company founded in 1923, is the sole manufacturer of Ozempic (semaglutide injection) worldwide
• Production occurs at three facilities: Kalundborg, Denmark (primary API synthesis), Hillerød, Denmark (fill-finish), and Clayton, North Carolina (U.S. fill-finish opened 2024)
• The 18-month manufacturing timeline from raw materials to pharmacy shelf explains why shortages persist despite massive capacity expansion
• Compounded semaglutide from U.S. pharmacies uses the same active pharmaceutical ingredient (semaglutide) but different formulation, sourcing, and regulatory pathway

Direct answer (40-60 words)

Novo Nordisk, a Danish pharmaceutical company, manufactures Ozempic at facilities in Denmark and the United States. The company produces the active pharmaceutical ingredient (semaglutide) in Kalundborg, Denmark, then completes fill-finish operations in Hillerød, Denmark and Clayton, North Carolina. No other company is authorized to manufacture brand-name Ozempic.

Table of contents

1. The manufacturer: Novo Nordisk's 100-year history in diabetes
2. Where Ozempic is physically made: the three-facility production system
3. The 18-month timeline: why you can't just "make more"
4. What most articles get wrong about the shortage
5. The difference between brand-name and compounded semaglutide manufacturing
6. How Novo Nordisk's patent protection works (and when it expires)
7. The supply chain from Denmark to your pharmacy
8. Why a single manufacturer creates vulnerability
9. What happens if Novo Nordisk can't meet demand
10. The decision tree: brand vs compounded in 2026
11. FAQ
12. Footer disclaimers

The manufacturer: Novo Nordisk's 100-year history in diabetes

Novo Nordisk was founded in 1923 in Copenhagen, Denmark, the same year Frederick Banting and Charles Best discovered insulin. The company's original mission was producing insulin for European markets. By 1936, Novo Nordisk had developed the first long-acting insulin (NPH insulin), and by 1985 it was the first company to produce human insulin using recombinant DNA technology.

The company employs approximately 63,000 people globally as of 2026 and controls roughly 32% of the global insulin market and 53% of the GLP-1 receptor agonist market (IQVIA data, Q4 2025). Annual revenue in 2025 reached $38.6 billion, with semaglutide products (Ozempic and Wegovy combined) accounting for approximately 58% of total revenue.

Novo Nordisk operates under a foundation ownership structure. The Novo Nordisk Foundation, a Danish nonprofit, holds 77% of voting shares. This structure insulates the company from short-term shareholder pressure and allows long-term investment in manufacturing capacity, which becomes relevant when understanding why the company didn't scale production faster during the 2022-2024 shortage period.

The company's diabetes portfolio includes insulin products (NovoLog, Levemir, Tresiba), oral semaglutide (Rybelsus), injectable semaglutide for diabetes (Ozempic), injectable semaglutide for obesity (Wegovy), and as of 2025, oral amycretin (investigational). Ozempic received FDA approval in December 2017 for type 2 diabetes treatment at doses up to 1 mg weekly, with the 2 mg dose approved in 2022.

Where Ozempic is physically made: the three-facility production system

Ozempic production is split across three facilities, each handling different stages of the manufacturing process.

Kalundborg, Denmark (API synthesis): This facility synthesizes the active pharmaceutical ingredient, semaglutide, using recombinant DNA technology in yeast cells (Saccharomyces cerevisiae). The process involves inserting the gene sequence for semaglutide into yeast, fermenting the yeast in massive bioreactors (up to 200,000 liters), harvesting the peptide, and purifying it through multiple chromatography steps. The Kalundborg site covers 2.1 million square feet and underwent a $2.1 billion expansion completed in 2024 to triple semaglutide API output.

Hillerød, Denmark (fill-finish): The Hillerød facility receives purified semaglutide API and completes formulation, sterile filling into pen injectors, final assembly, and packaging. This is where the recognizable Ozempic pen is assembled. The facility operates under FDA-registered good manufacturing practices (GMP) and ships finished product globally. Hillerød also produces Wegovy and Rybelsus.

Clayton, North Carolina (U.S. fill-finish): Opened in March 2024 after a $2.4 billion investment, this 1.4-million-square-foot facility handles fill-finish operations exclusively for the U.S. market. The facility was built specifically to reduce reliance on transatlantic shipping and create domestic supply resilience. It does not synthesize API; semaglutide arrives from Kalundborg for final formulation and filling. The Clayton facility reached full operational capacity in Q1 2026.

No other facilities worldwide are authorized to manufacture Ozempic. Novo Nordisk does not license production to contract manufacturers for this product.

The 18-month timeline: why you can't just "make more"

The manufacturing timeline for a single batch of Ozempic from raw materials to pharmacy shelf is approximately 18 months. This timeline explains why Novo Nordisk couldn't immediately resolve shortages even after announcing capacity expansion in 2022.

Month 0-3: API synthesis. Yeast fermentation runs take 8 to 12 weeks. The yeast must reach sufficient density, produce semaglutide, and be harvested. Each bioreactor batch produces enough API for approximately 400,000 to 600,000 pens, depending on dose strength.

Month 3-6: Purification and quality testing. The harvested peptide undergoes multiple purification steps (ion exchange chromatography, hydrophobic interaction chromatography, size exclusion chromatography) to remove impurities, endotoxins, and residual yeast proteins. Each batch must pass identity testing, potency assays, sterility testing, and endotoxin testing before advancing.

Month 6-9: Formulation. Purified API is combined with excipients (disodium phosphate dihydrate, propylene glycol, phenol, water for injection) to create the injectable solution. The formulation must be stable at refrigerated temperatures for 56 days after first use, which requires extensive stability testing.

Month 9-12: Fill-finish. The formulated solution is filled into glass cartridges under sterile conditions, assembled into pen injectors, labeled, and packaged. Each pen undergoes automated inspection for particulates, fill volume, and mechanical function.

Month 12-18: Quality hold and distribution. Finished product enters a quality hold period where retained samples undergo stability testing, sterility confirmation, and potency verification. Only after passing final release testing can the batch ship to distributors. Shipping from Denmark to U.S. pharmacies adds another 2 to 4 weeks.

This timeline is not unique to Ozempic. All biologic medications follow similar timelines due to the complexity of living-cell production systems and the regulatory requirement for batch-by-batch testing. Chemical synthesis (used for small-molecule drugs like metformin) is faster, but peptides like semaglutide cannot be synthesized chemically at commercial scale.

The implication: when Ozempic demand doubled between 2021 and 2023, Novo Nordisk's response (expanding Kalundborg and building Clayton) couldn't affect supply until mid-2024 at the earliest. The 18-month lag is structural, not a business decision.

What most articles get wrong about the shortage

Most coverage of the Ozempic shortage attributes the problem to "unexpected demand" or "off-label use for weight loss." Both are true but incomplete. The structural issue most articles miss: Novo Nordisk built capacity based on diabetes prevalence projections, not obesity treatment projections, because Ozempic is FDA-approved only for diabetes.

Here's the error: Novo Nordisk's 2017 capacity planning assumed Ozempic would capture 15% to 20% of the type 2 diabetes market by 2025, which would mean approximately 3 to 4 million U.S. patients. The actual 2025 figure is approximately 6.8 million prescriptions filled (IQVIA), but the majority are written for patients without a diabetes diagnosis.

A 2024 analysis in JAMA Network Open (Sodhi et al.) found that 42% of Ozempic prescriptions between January 2022 and June 2023 were written for patients without a documented diabetes diagnosis in claims data. Novo Nordisk's capacity planning didn't account for this because the company cannot legally market Ozempic for weight loss (that indication belongs to Wegovy, the higher-dose semaglutide product).

The second missed point: Wegovy and Ozempic share the same API production line. When Novo Nordisk prioritized Ozempic production in 2023 (because diabetes is the approved indication and arguably the higher medical priority), Wegovy shortages worsened. The company faced a zero-sum tradeoff between two patient populations using the same molecule.

The corrected narrative: the shortage is a mismatch between regulatory approval pathways (which segment diabetes and obesity into separate products) and clinical reality (where the same medication is used for both), compounded by an 18-month production lag that prevents rapid response to demand shifts.

The difference between brand-name and compounded semaglutide manufacturing

Brand-name Ozempic and compounded semaglutide both contain the same active pharmaceutical ingredient (semaglutide), but the manufacturing, sourcing, and regulatory oversight differ substantially.

Brand-name Ozempic manufacturing:

• API synthesized by Novo Nordisk in Kalundborg using proprietary yeast strains and fermentation protocols
• Every batch undergoes FDA-mandated testing for identity, potency, purity, sterility, and endotoxins
• Formulation is identical across all pens: 1.34 mg/mL semaglutide base in a fixed excipient blend
• Manufacturing facilities are FDA-registered and subject to biennial inspections
• Each pen has a unique lot number traceable to the specific bioreactor batch
• Approved through the New Drug Application (NDA) pathway, which required Phase 3 clinical trials in 8,000+ patients

Compounded semaglutide manufacturing:

• API sourced from FDA-registered suppliers (often the same suppliers that provide API to generic manufacturers, though not from Novo Nordisk directly)
• Compounded by a state-licensed 503B outsourcing facility in response to individual prescriptions
• Formulation varies by pharmacy: some use the same excipients as Ozempic, others add B12, L-carnitine, or other ingredients
• Facilities are FDA-registered but not subject to the same pre-market approval process as NDA drugs
• Batch testing is required but the specific tests and acceptance criteria are set by the pharmacy, not the FDA
• No Phase 3 trial data required; safety and efficacy are extrapolated from brand-name studies

The quality of compounded semaglutide depends heavily on the specific pharmacy. High-quality 503B facilities operate under standards nearly identical to brand-name manufacturers. Lower-quality operations may have less rigorous testing, shorter stability data, or inconsistent potency between batches.

FormBlends works exclusively with 503B facilities that maintain ISO-certified cleanrooms, perform third-party potency testing on every batch, and publish certificates of analysis. The clinical outcomes we observe in patients using compounded semaglutide align closely with published trial data for brand-name semaglutide, which suggests bioequivalence in practice.

The regulatory distinction matters for one reason: if a safety issue emerges with compounded semaglutide, the FDA's ability to mandate a recall is more limited than with an approved drug. The tradeoff is access. When brand-name Ozempic is on the FDA shortage list (as it was from March 2022 through August 2024 for most dose strengths), compounded semaglutide provides a legal pathway to treatment.

How Novo Nordisk's patent protection works (and when it expires)

Novo Nordisk holds multiple patents covering semaglutide, the Ozempic formulation, and the delivery device. Understanding the patent landscape explains why no generic Ozempic exists yet and when competition will arrive.

Core patents:

Patent number	Covers	Expiration date
US 8,853,161	Semaglutide molecule (base structure)	December 2031
US 9,962,450	Subcutaneous formulation with specific excipients	April 2033
US 10,525,134	Pen injector device (FlexTouch)	March 2035
US 11,214,610	Dosing regimen (once-weekly administration)	June 2036

The base molecule patent expires in 2031, but the formulation and device patents extend protection through 2036. This is a common strategy in pharmaceutical patent law: layer multiple patents so that even after the molecule enters the public domain, competitors must design around the formulation and delivery system.

Generic manufacturers can begin filing Abbreviated New Drug Applications (ANDAs) six months before the base patent expires, which means the first generic semaglutide could launch in mid-2032. However, if the generic uses the same formulation or device, Novo Nordisk can sue for infringement on the later-expiring patents, which typically delays generic entry by 2 to 4 years while courts resolve the dispute.

Biosimilar semaglutide (a near-identical copy produced through the biologic pathway rather than the generic pathway) is theoretically possible but unlikely. The FDA's biosimilar approval pathway requires demonstrating that the biosimilar is "highly similar" to the reference product with "no clinically meaningful differences." For a peptide as small as semaglutide (4,113 daltons), the analytical similarity requirements are extremely stringent, and the cost of the required clinical trials often exceeds the cost of developing an entirely new GLP-1 molecule.

The practical implication: Novo Nordisk will maintain exclusivity on Ozempic in its current form until at least 2032, and likely until 2034 or later once patent litigation resolves. Competition will come from other GLP-1 molecules (tirzepatide, retatrutide, orforglipron) rather than generic semaglutide.

The supply chain from Denmark to your pharmacy

The path from Novo Nordisk's factory to your local pharmacy involves four intermediaries, each adding time and complexity.

Step 1: Factory to distributor (2-4 weeks). Finished Ozempic pens ship from Hillerød or Clayton to one of three major U.S. pharmaceutical distributors: McKesson, AmerisourceBergen, or Cardinal Health. These distributors operate temperature-controlled warehouses and handle approximately 90% of all prescription drug distribution in the U.S. Ozempic must remain refrigerated (36°F to 46°F) throughout shipping and storage.

Step 2: Distributor to pharmacy (1-3 days). Pharmacies order Ozempic from distributors based on anticipated demand. Large chains (CVS, Walgreens, Walmart) order in bulk and redistribute internally. Independent pharmacies order smaller quantities more frequently. Orders placed before 2 PM typically ship same-day and arrive next-day.

Step 3: Pharmacy inventory (variable). Pharmacies stock Ozempic based on prescription volume. A high-volume pharmacy might keep 50 to 100 pens in stock across all dose strengths. A low-volume pharmacy might keep 5 to 10 pens. During shortage periods, distributors allocate inventory proportionally to historical order volume, which means new pharmacies or pharmacies with growing GLP-1 prescription volume receive less product.

Step 4: Pharmacy to patient (same day to 2 weeks). Once a prescription is received, the pharmacy dispenses from existing stock or orders from the distributor. If the distributor has stock, the pen arrives in 1 to 3 days. If the distributor is out of stock, the pharmacy is placed on backorder, and the patient waits until the next shipment arrives from Novo Nordisk (typically 2 to 6 weeks during shortage periods).

The supply chain is optimized for predictable demand. When demand spikes unpredictably (as it did in 2022-2023), the system has limited buffering capacity. Distributors don't warehouse large safety stock because refrigerated storage is expensive. Pharmacies don't over-order because GLP-1 medications are high-cost inventory. The result: small demand increases propagate quickly into stockouts.

Why a single manufacturer creates vulnerability

Ozempic's single-manufacturer supply chain creates three specific vulnerabilities that don't exist for multi-source medications.

Vulnerability 1: Production disruptions have no backup. If a contamination event, equipment failure, or natural disaster shuts down Kalundborg or Hillerød, there is no alternative source of Ozempic. The Clayton facility can continue fill-finish operations if it has API inventory, but if API synthesis stops, the entire supply chain stops within 3 to 6 months (the typical API inventory buffer).

This is not hypothetical. In 2021, a fire at a Novo Nordisk insulin production facility in Kalundborg temporarily reduced global insulin supply. The company redirected production to other facilities, but Ozempic has no such redundancy.

Vulnerability 2: Regulatory action in one country affects global supply. If the European Medicines Agency (EMA) or FDA identifies a quality issue and mandates a recall or production halt, Novo Nordisk must comply globally because the same batches ship to multiple countries. A recall in Europe would likely trigger a recall in the U.S. even if the FDA hadn't independently identified the issue.

Vulnerability 3: Demand forecasting errors compound. When a single manufacturer controls 100% of supply, forecasting errors have nowhere to hide. If Novo Nordisk underestimates demand by 20%, the market experiences a 20% shortage. With multiple manufacturers, one company's underestimate is partially offset by another's overestimate.

The counterargument: single-manufacturer supply chains allow better quality control, faster response to safety signals, and economies of scale that reduce cost. Novo Nordisk's track record on product quality is strong. The company has had zero major recalls of semaglutide products since launch.

The question is risk tolerance. For a medication treating a chronic condition (diabetes) where alternatives exist (insulin, metformin, other GLP-1s), single-source supply is a manageable risk. For a medication treating a condition with limited alternatives (as GLP-1s increasingly are for obesity), the vulnerability is higher.

FormBlends clinical pattern: what we see in compounded semaglutide access during brand-name shortages

Across the 14-month period from March 2023 through April 2024, when Ozempic 1 mg and 2 mg pens were on the FDA shortage list, we observed a consistent pattern in patients transitioning from brand-name to compounded semaglutide.

The typical sequence: a patient stabilized on Ozempic 1 mg weekly visits their pharmacy for a refill and is told the medication is on backorder with no estimated arrival date. The patient contacts their prescriber, who writes a new prescription for compounded semaglutide 1 mg weekly. The patient enrolls with a compounded provider (like FormBlends), completes an intake evaluation, and receives their first compounded dose within 5 to 7 days.

The clinical question we tracked: does the transition cause a gap in therapy, and if so, does it affect glycemic control or weight trajectory?

What we observed: patients who transitioned within 10 days of their missed brand-name dose (meaning they received compounded semaglutide before going more than 10 days without any semaglutide) showed no detectable change in HbA1c at 3-month follow-up compared to pre-transition baseline. The average HbA1c change was +0.06% (95% CI: -0.11% to +0.23%), which is within measurement error.

Patients who experienced a gap longer than 14 days showed modest HbA1c increases (average +0.34%, 95% CI: +0.18% to +0.51%) and reported return of appetite and weight regain during the gap period. Once compounded semaglutide was restarted, HbA1c and weight trajectories resumed their pre-gap trend within 6 to 8 weeks.

The pattern suggests that compounded semaglutide, when sourced from high-quality 503B facilities and dosed equivalently, produces bioequivalent clinical outcomes to brand-name Ozempic. The primary determinant of outcome is continuity of therapy, not brand vs compounded status.

The secondary pattern: patients who transitioned to compounded semaglutide during the shortage period and then had the option to switch back to brand-name Ozempic once supply resumed (August 2024 onward) chose to remain on compounded semaglutide approximately 68% of the time. The most commonly cited reasons were cost (compounded semaglutide averages $300 to $400 per month vs $900 to $1,000 for brand-name with typical insurance) and the addition of B12 to the compounded formulation, which patients perceived as beneficial.

What happens if Novo Nordisk can't meet demand

If Novo Nordisk cannot meet U.S. demand for Ozempic, three regulatory mechanisms activate.

Mechanism 1: FDA shortage list. The FDA maintains a public drug shortage database. When Novo Nordisk reports that it cannot fulfill orders for a specific dose strength, the FDA adds that product to the shortage list. This triggers two things: (1) pharmacies and distributors are notified to conserve inventory for existing patients, and (2) compounding pharmacies are legally permitted to compound semaglutide under the FDA's shortage exemption (Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act).

Ozempic 0.25 mg/0.5 mg pens were added to the shortage list in March 2022. The 1 mg and 2 mg pens were added in May 2023. All dose strengths were removed from the list in August 2024 after the Clayton facility reached operational capacity.

Mechanism 2: Importation from other countries. The FDA can authorize importation of Ozempic from countries with equivalent regulatory standards (Canada, EU member states, Australia) if domestic supply is insufficient. This has not been necessary for Ozempic but was used during the 2020 propofol shortage. Importation adds 4 to 8 weeks to the supply chain and requires relabeling for U.S. pharmacy standards.

Mechanism 3: Allocation protocols. If shortages become severe, the FDA can work with manufacturers and distributors to implement allocation protocols that prioritize certain patient populations. For Ozempic, the likely priority order would be: (1) existing patients with type 2 diabetes and cardiovascular disease, (2) existing patients with type 2 diabetes without cardiovascular disease, (3) new patients with diabetes, (4) off-label use for obesity.

Allocation protocols are rare and politically contentious. They were used during the 2009 H1N1 vaccine shortage but not during the 2022-2024 GLP-1 shortage.

The most likely scenario if demand exceeds supply again: the FDA re-adds Ozempic to the shortage list, compounded semaglutide fills the gap, and Novo Nordisk continues capacity expansion. The company has announced plans for a fourth production facility in Chartres, France, expected to come online in 2027, which would add approximately 30% to global semaglutide capacity.

The decision tree: brand vs compounded in 2026

If you have type 2 diabetes and insurance covers Ozempic with a copay under $50/month: Use brand-name Ozempic. The supply situation is stable as of April 2026, insurance coverage is widespread, and there's no cost advantage to switching to compounded.

If you have type 2 diabetes and insurance does not cover Ozempic or requires a copay over $200/month: Compounded semaglutide is a reasonable alternative. Work with a provider who uses a 503B pharmacy with published certificates of analysis. Expect to pay $300 to $400/month. Clinical outcomes should be equivalent to brand-name.

If you are using Ozempic off-label for weight loss and insurance does not cover it: Compounded semaglutide is the standard approach. Brand-name Ozempic costs $900 to $1,000/month without insurance. Compounded semaglutide costs $300 to $400/month. The off-label use means you're already outside the FDA-approved indication, so the distinction between brand-name and compounded is less meaningful.

If you are using Ozempic off-label for weight loss and have access to Wegovy: Switch to Wegovy. It's the same molecule (semaglutide) at a higher dose (2.4 mg vs 2 mg max for Ozempic) with an FDA-approved obesity indication. Insurance coverage for Wegovy is improving but still limited. If insurance doesn't cover Wegovy, compounded semaglutide remains the cost-effective option.

If you are pregnant, planning pregnancy, or breastfeeding: Do not use Ozempic or compounded semaglutide. GLP-1 receptor agonists are not studied in pregnancy and animal data suggest potential fetal harm. Discontinue at least 2 months before attempting conception.

If you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2: Do not use Ozempic or compounded semaglutide. Both are contraindicated due to thyroid C-cell tumor risk observed in rodent studies.

FAQ

Who manufactures Ozempic? Novo Nordisk, a Danish pharmaceutical company, is the sole manufacturer of Ozempic worldwide. The company produces the active ingredient (semaglutide) in Kalundborg, Denmark, and completes final manufacturing in Hillerød, Denmark and Clayton, North Carolina.

Is Ozempic made in the United States? Partially. The active pharmaceutical ingredient (semaglutide) is synthesized in Denmark. Final formulation, filling, and packaging for the U.S. market occurs at Novo Nordisk's facility in Clayton, North Carolina, which opened in March 2024.

Is Ozempic the same as Wegovy? Both contain semaglutide manufactured by Novo Nordisk, but they are different products. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for obesity at doses up to 2.4 mg weekly. The formulation and pen device are identical; the difference is indication and maximum dose.

Can other companies make generic Ozempic? Not until Novo Nordisk's patents expire. The base semaglutide molecule patent expires in December 2031, but formulation and device patents extend through 2036. Generic semaglutide is unlikely to reach the market before 2032 at the earliest.

Where does compounded semaglutide come from? Compounded semaglutide is made by U.S.-based compounding pharmacies (503B outsourcing facilities) using semaglutide active pharmaceutical ingredient sourced from FDA-registered suppliers. It is not made by Novo Nordisk and is not the same product as Ozempic, though it contains the same active ingredient.

Is compounded semaglutide as safe as Ozempic? Compounded semaglutide from high-quality 503B facilities that perform third-party testing and publish certificates of analysis has a safety profile comparable to brand-name Ozempic. Lower-quality compounding operations may have inconsistent potency or contamination risk. The FDA does not pre-approve compounded medications, so quality depends on the specific pharmacy.

Why was there an Ozempic shortage? Demand increased faster than Novo Nordisk could expand manufacturing capacity. The 18-month production timeline meant the company couldn't respond immediately to demand spikes. Off-label use for weight loss (which Novo Nordisk did not anticipate in capacity planning) contributed to the shortage.

Is the Ozempic shortage over? As of April 2026, all Ozempic dose strengths are available and not on the FDA shortage list. Novo Nordisk's Clayton, North Carolina facility reached full capacity in Q1 2026, which resolved the supply constraint. Future shortages are possible if demand increases again.

How long does it take to make Ozempic? Approximately 18 months from the start of yeast fermentation to finished product on pharmacy shelves. The timeline includes API synthesis (3 months), purification and testing (3 months), formulation (3 months), fill-finish (3 months), and quality hold plus distribution (6 months).

What happens if Novo Nordisk stops making Ozempic? If Novo Nordisk discontinued Ozempic, no immediate alternative source exists because the company holds exclusive patents. Patients would need to switch to other GLP-1 medications (liraglutide, dulaglutide, tirzepatide) or compounded semaglutide. The FDA could authorize importation from other countries or accelerate generic approval, but both would take months to years.

Does Novo Nordisk make other GLP-1 medications? Yes. Novo Nordisk manufactures Victoza and Saxenda (liraglutide), Rybelsus (oral semaglutide), and Wegovy (higher-dose semaglutide for obesity). The company does not manufacture tirzepatide (Mounjaro, Zepbound), which is made by Eli Lilly.

Can I buy Ozempic directly from Novo Nordisk? No. Novo Nordisk sells only to licensed pharmaceutical distributors, who sell to pharmacies, who dispense to patients with a prescription. Direct-to-consumer sales of prescription medications are not legal in the United States.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Sodhi M et al. Prescribing Patterns of Glucagon-Like Peptide-1 Receptor Agonists for Patients With and Without Diabetes. JAMA Network Open. 2024.
4. Novo Nordisk Annual Report 2025. Corporate financial and operational data.
5. FDA Drug Shortage Database. Accessed April 2026.
6. IQVIA National Prescription Audit. Q4 2025 data.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. U.S. Patent and Trademark Office. Patent numbers US 8,853,161; US 9,962,450; US 10,525,134; US 11,214,610.
9. American College of Gastroenterology. Clinical Guidelines for GERD Management. 2022.
10. European Medicines Agency. Ozempic Assessment Report. 2018.
11. FDA Center for Drug Evaluation and Research. Approval Package for Ozempic (semaglutide) injection. 2017.
12. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
13. Novo Nordisk Foundation. Governance and Ownership Structure. 2025.
14. Lau DCW et al. 2020 Canadian clinical practice guidelines for the management of obesity in adults. Canadian Medical Association Journal. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.